AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24075291 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Alzheimer's Disease Assessment Scale-cognitive section (SADAS‐cog)
Number of subjects: 406
Study 24075291 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating (CDR) scale
Number of subjects: 406
Study 24075291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawton‐Brady activities of daily living (ADL) scale
Number of subjects: 406
Study 23745636 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing intervention
Number of subjects: 0
Study 21169060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab with first-cycle rash
Number of subjects: 518
Study 21169060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab without first-cycle rash
Number of subjects: 518
Study 18794757 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior spinal fusion (ASF) with single solid rod and single screw constructs
Number of subjects: 32
Study 18794757 — intervention group
Group type: COMPARATOR
Intervention: Posterior spinal fusion (PSF) with segmental total pedicle screw system
Number of subjects: 32
Study 17062685 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Vinorelbine (DV)
Number of subjects: 64
Study 17062685 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Estramustine (DE)
Number of subjects: 64
Study 17062685 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCG2 421 C > A (Q141K) polymorphism
Number of subjects: 64
Study 12712781 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (ARS)
Number of subjects: 24
Study 12712781 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized mechanical ventilation)
Number of subjects: 24
Study 11107075 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 399
Study 11107075 — intervention group
Group type: COMPARATOR
Intervention: PTFE Patch Closure
Number of subjects: 399
Study 11107075 — intervention group
Group type: COMPARATOR
Intervention: PTFE Patch Closure and Vein Patch Closure (VPC)
Number of subjects: 399
Study 11107075 — intervention group
Group type: COMPARATOR
Intervention: Normal Duplex Scan Findings at 6 Months (Patched Arteries)
Number of subjects: 399
Study 8957369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 704
Study 8957369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 704
Study 8957369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump-prime-only aprotinin
Number of subjects: 704
Study 8957369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 1416125 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% end‐tidal isoflurane in O2
Number of subjects: 20
Study 1416125 — intervention group
Group type: COMPARATOR
Intervention: 70% N2O in O2
Number of subjects: 20
Study 2989349 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 10 mg orally)
Number of subjects: 23
Study 2989349 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (long-term treatment)
Number of subjects: 23
Study 2989349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (long-term treatment)
Number of subjects: 23
Study 30025837 — intervention group
Group type: EXPERIMENTAL
Intervention: Push‐Ortho‐Thumb‐Brace‐CMC
Number of subjects: 16
Study 30025837 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐made orthosis
Number of subjects: 16
Study 30257655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Prevention Practitioner (PP) visit
Number of subjects: 0
Study 30257655 — intervention group
Group type: COMPARATOR
Intervention: Standard care (wait-list control)
Number of subjects: 0
Study 27216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic diet
Number of subjects: 13
Study 27216013 — intervention group
Group type: COMPARATOR
Intervention: Diabetes diet
Number of subjects: 13
Study 25453518 — intervention group
Group type: EXPERIMENTAL
Intervention: co-supplemented hemp seed and evening primrose oils with advised Hot-nature diet
Number of subjects: 100
Study 25453518 — intervention group
Group type: EXPERIMENTAL
Intervention: co-supplemented oils
Number of subjects: 100
Study 25453518 — intervention group
Group type: COMPARATOR
Intervention: olive oil
Number of subjects: 100
Study 22370434 — intervention group
Group type: EXPERIMENTAL
Intervention: better weight (BW) cognitive behavioral intervention
Number of subjects: 49
Study 22370434 — intervention group
Group type: COMPARATOR
Intervention: better weight-better sleep (BWBS) intervention
Number of subjects: 49
Study 20974575 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg once daily
Number of subjects: 222
Study 20974575 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 222
Study 20974575 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir twice daily for 3 months then once daily
Number of subjects: 222
Study 20974575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior NRTI resistance
Number of subjects: 222
Study 20974575 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior NRTI resistance
Number of subjects: 222
Study 18580206 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drain
Number of subjects: 69
Study 18580206 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 69
Study 17017631 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid whitening gel (5.9% hydrogen peroxide, twice a day for 15 minutes)
Number of subjects: 60
Study 17017631 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorite‐based whitening gel applied in a tray system (10 minutes twice a day)
Number of subjects: 60
Study 14617500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pager reminder system
Number of subjects: 0
Study 14617500 — intervention group
Group type: COMPARATOR
Intervention: Monitoring only
Number of subjects: 0
Study 10594426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 29
Study 10594426 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 29
Study 10594426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 8922488 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (n = 48)
Number of subjects: 87
Study 8922488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 87
Study 1405245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin‐retard (n = 20; Group 1)
Number of subjects: 50
Study 1405245 — intervention group
Group type: EXPERIMENTAL
Intervention: Corovas (n = 20; Group 2)
Number of subjects: 50
Study 1405245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10; Group 3)
Number of subjects: 50
Study 2860739 — intervention group
Group type: EXPERIMENTAL
Intervention: STA‐MCA bypass in addition to medical therapy (daily aspirin and aggressive hypertension control)
Number of subjects: 1377
Study 2860739 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (daily aspirin and aggressive hypertension control)
Number of subjects: 1377
Study 31836434 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + letrozole
Number of subjects: 666
Study 31836434 — intervention group
Group type: COMPARATOR
Intervention: Placebo + letrozole
Number of subjects: 666
Study 31563038 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 30
Study 31563038 — intervention group
Group type: COMPARATOR
Intervention: Control session (resting and reading magazines)
Number of subjects: 30
Study 28625036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago worm inclusive diet (100 g per day for 45 days)
Number of subjects: 23
Study 28625036 — intervention group
Group type: COMPARATOR
Intervention: Control group eating a usual diet without sago worms
Number of subjects: 23
Study 28625036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago worm inclusive diet
Number of subjects: 23
Study 26309676 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-breathing training
Number of subjects: 42
Study 26309676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 42
Study 26309676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of deep-breathing exercises and oxygen inhalation
Number of subjects: 42
Study 23648640 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (0, 250, 375, or 500 mg/d)
Number of subjects: 41
Study 23648640 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study 22215944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine swab
Number of subjects: 80
Study 22215944 — intervention group
Group type: COMPARATOR
Intervention: Spray
Number of subjects: 80
Study 17852792 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD/NMD during normoxia (21% O2, 79% N2)
Number of subjects: 20
Study 17852792 — intervention group
Group type: EXPERIMENTAL
Intervention: FMDHyp/NMD during inhaling hypoxic gas (12.5% O2)
Number of subjects: 20
Study 17852792 — intervention group
Group type: EXPERIMENTAL
Intervention: FMDO2/NMD during 100% O2 supplementation
Number of subjects: 20
Study 17852792 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 20
Study 16492207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (initial dose 15 mg/day, increased to 30 mg/day)
Number of subjects: 30
Study 16492207 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (initial dose 0.6 mg/day, increased to 0.9 mg/day)
Number of subjects: 30
Study 15611421 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Allergen Replacement Database group
Number of subjects: 29
Study 15611421 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy group
Number of subjects: 29
Study 11515703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 708
Study 11515703 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 708
Study 9294378 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication alone for 14 months
Number of subjects: 576
Study 9294378 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment alone for 14 months
Number of subjects: 576
Study 9294378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and psychosocial treatment for 14 months
Number of subjects: 576
Study 9294378 — intervention group
Group type: COMPARATOR
Intervention: Community comparison (routine community care)
Number of subjects: 576
Study 8403175 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly dosed oral morphine (20 mg every four hours)
Number of subjects: 47
Study 8403175 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (equivalent dose every four hours)
Number of subjects: 47
Study 3956052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 42
Study 3956052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 42
Study 3956052 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 42
Study 3956052 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 42
Study 31472099 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient treatment
Number of subjects: 0
Study 31472099 — intervention group
Group type: COMPARATOR
Intervention: Diaper dermatitis group
Number of subjects: 0
Study 30033655 — intervention group
Group type: EXPERIMENTAL
Intervention: Who's Challenging Who? training
Number of subjects: 236
Study 30033655 — intervention group
Group type: COMPARATOR
Intervention: Delayed training (control group)
Number of subjects: 236
Study 27716604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg, oral, twice a day for 4 weeks)
Number of subjects: 50
Study 27716604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, oral, twice a day for 4 weeks)
Number of subjects: 50
Study 22639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment
Number of subjects: 0
Study 22639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Planimetry assessment
Number of subjects: 0
Study 22555328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor, 50 mg/kg/day, administered twice daily for five days
Number of subjects: 435
Study 22555328 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate, 40 mg/kg/day administered twice daily for 10 days
Number of subjects: 435
Study 20380787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with leg pain
Number of subjects: 120
Study 20380787 — intervention group
Group type: COMPARATOR
Intervention: Normal and pain control subjects
Number of subjects: 120
Study 18039994 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 610
Study 18039994 — intervention group
Group type: COMPARATOR
Intervention: Anxiety assessment
Number of subjects: 610
Study 16105921 — intervention group
Group type: COMPARATOR
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 40
Study 16105921 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Repair (OR)
Number of subjects: 40
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg kg‐1
Number of subjects: 120
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg kg‐1
Number of subjects: 120
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.22 mg kg‐1
Number of subjects: 120
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg‐1
Number of subjects: 120
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 120
Study 12378667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.29 mg kg‐1 (ED95)
Number of subjects: 120
Study 12378667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10529324 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase therapy with r-hirudin or heparin
Number of subjects: 1208
Study 10529324 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST segment elevation resolution (<30%) at 90 min
Number of subjects: 1208
Study 10529324 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST segment elevation resolution (<30%) at 180 min
Number of subjects: 1208
Study 7775684 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 20
Study 7775684 — intervention group
Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 20
Study 2270358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg.kg‐1.h‐1
Number of subjects: 10
Study 2270358 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 10
Study 531232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg x 3)
Number of subjects: 18
Study 531232 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (25 mg x 3)
Number of subjects: 18
Study 531232 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (0.5 g x 3)
Number of subjects: 18
Study 531232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31045851 — intervention group
Group type: EXPERIMENTAL
Intervention: HeadCoach online manager training
Number of subjects: 210
Study 31045851 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 210
Study 29944435 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic symptom reporting
Number of subjects: 21
Study 27643994 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) assessments focusing on symptoms of psychosis
Number of subjects: 1
Study 27643994 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic focus on 'paranoia' as the most central symptom
Number of subjects: 1
Study 24052453 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Care Management (ACM)
Number of subjects: 163
Study 24052453 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in specialty outpatient addiction treatment program
Number of subjects: 163
Study 22703421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 μg
Number of subjects: 652
Study 22703421 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 iu
Number of subjects: 652
Study 19224679 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTS infusion intervention
Number of subjects: 404
Study 19224679 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 404
Study 17805075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (30 microg of ethinyl estradiol and 0.3 mg of norgestrel) for 2 years
Number of subjects: 150
Study 17805075 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study 15356032 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids and carbohydrates supplementation (16.5 g essential amino acids and 30 g carbohydrates at 1100, 1600, and 2100 h)
Number of subjects: 0
Study 15356032 — intervention group
Group type: COMPARATOR
Intervention: Control group received a nutritionally mixed meal every 5 hours (0830, 1330, and 1830 h)
Number of subjects: 0
Study 15356032 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids and carbohydrates supplementation
Number of subjects: 0
Study 15356032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12174005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micro g/kg orally
Number of subjects: 110
Study 12174005 — intervention group
Group type: COMPARATOR
Intervention: 10% benzyl benzoate topically
Number of subjects: 110
Study 10442367 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 IV infusion on day 1) and UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Number of subjects: 20
Study 10442367 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Number of subjects: 20
Study 10442367 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 IV infusion on day 1)
Number of subjects: 20
Study 10442367 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (600 mg/day orally)
Number of subjects: 20
Study 7822661 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of budesonide per day
Number of subjects: 19
Study 7822661 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of budesonide per day
Number of subjects: 19
Study 7822661 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of budesonide per day
Number of subjects: 19
Study 7822661 — intervention group
Group type: COMPARATOR
Intervention: Budesonide doses
Number of subjects: 19
Study 2218423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 270
Study 2218423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 270
Study 2218423 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactams (including imipenem/cilastatin, ticarcillin/clavulanic acid, cefpirome)
Number of subjects: 270
Study 708024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg doxycycline (or 4 mg/kg in patients less than 15 years old)
Number of subjects: 65
Study 708024 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of doxycycline, 500 mg over 4 days (or 10 mg/kg in patients less than 15 years old)
Number of subjects: 65
Study 708024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 708024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg doxycycline (or 4 mg/kg in children)
Number of subjects: 65
Study 30418098 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive systolic blood pressure lowering treatment
Number of subjects: 0
Study 28052471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education computer game
Number of subjects: 109
Study 28052471 — intervention group
Group type: COMPARATOR
Intervention: One-to-one education
Number of subjects: 109
Study 28052471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods of education
Number of subjects: 109
Study 25676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining positive outcomes of non‐drinking during a social occasion
Number of subjects: 211
Study 25676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining strategies required for non‐drinking during a social occasion
Number of subjects: 211
Study 25676207 — intervention group
Group type: COMPARATOR
Intervention: Combined condition (imagining both positive outcomes and required strategies)
Number of subjects: 211
Study 25676207 — intervention group
Group type: COMPARATOR
Intervention: Control condition (completing a drinks diary task)
Number of subjects: 211
Study 23416718 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (2 ng.ml‐1 target)
Number of subjects: 40
Study 23416718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 ng.ml‐1 target)
Number of subjects: 40
Study 23416718 — intervention group
Group type: COMPARATOR
Intervention: Both opioids (Remifentanil and Sufentanil)
Number of subjects: 40
Study 20811168 — intervention group
Group type: COMPARATOR
Intervention: Brown envelope
Number of subjects: 2803
Study 20811168 — intervention group
Group type: COMPARATOR
Intervention: White envelope
Number of subjects: 2803
Study 20811168 — intervention group
Group type: COMPARATOR
Intervention: Brown envelopes (meta-analysis)
Number of subjects: 2803
Study 20811168 — intervention group
Group type: COMPARATOR
Intervention: White envelopes (meta-analysis)
Number of subjects: 2803
Study 20811168 — intervention group
Group type: COMPARATOR
Intervention: Brown envelopes (after excluding one study)
Number of subjects: 2803
Study 19373635 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow meter (PFM) action plan (n = 31)
Number of subjects: 63
Study 19373635 — intervention group
Group type: COMPARATOR
Intervention: Symptom-based action plan (n = 32)
Number of subjects: 63
Study 16923247 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (an inhibitor of xanthine oxidase)
Number of subjects: 0
Study 16923247 — intervention group
Group type: COMPARATOR
Intervention: Exercise (exhaustive physical exercise)
Number of subjects: 0